Pfizer (PFE) recently announced positive topline results from the Phase 3 EV-303 clinical trial, showcasing promising outcomes for PADCEV in treating muscle-invasive bladder cancer. Over the last ...

A new bladder cancer device called TAR-200 kept most patients cancer-free and surgery-free in a trial, with few side effects ...

Over the past 20 years, a class of cancer drugs called CD40 agonist antibodies have shown great promise—and induced great ...

For people facing aggressive bladder cancer that no longer responds to standard treatment, options have often been grim—either undergo life-changing surgery to remove the bladder or try less effective ...